Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon.

Schuette, W., Dietel, M., Thomas, M., Eberhardt, W., Zirrgiebel, U., Radke, S., Schirmacher, P., 2016.

Oncol Res Treat, 39 (suppl 1), (ID 0341) 120. doi:10.1159/000444354

Studie: REASON; Indikation: Bronchialkarzinom; Jahr: 2016; Veranstaltung: DKK; Journal: Oncology Research and Treatment

Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0